2020

Personalized/precision medicine, genomics, immunotherapy, and regenerative medicine are all approaches either under development or already being used separately and in combination to treat cancer. Speakers and panelists will provide the latest on these therapies, their business implications, and Indiana’s contribution to and role in their development.

Pictured: Philip Low, Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, Purdue University

2019

The opioid crisis Indiana and the country is facing came about through a combination of many factors – some well-intentioned and some unintended. Healthcare can play a major role in how to combat the crisis and what to replace opioids with going forward. Representatives from insurers, providers, pharma and med device companies will provide an overview and update on a wide range of initiatives and efforts currently ongoing.

Pictured: Jennifer Sullivan, MD, MPH, Former Secretary, Family and Social Services Administration

2018

The Changing Business of Healthcare

A number of potential new vertical combinations in healthcare have emerged. Whether these are approved or come to fruition remains to be seen. Nonetheless, the fact that all of these combinations are under consideration points to a tectonic shift in the business of healthcare delivery. Speakers and panelists will discuss the forces driving this and offer their thoughts on how the future is likely to shakeout.

Pictured: Don Brown, CEO, LifeOmic

2017

The New Administration’s Potential Impact on the Industry

Now that the new administration has been in place almost a year, the outlines of its policies for healthcare and the life sciences industry are beginning to emerge. Top administrators at the CMS and FDA are beginning to make their influence felt within their organizations. Speakers and panelists “connect the dots” as to the likely effects on things such as new product approvals, off-label usage, and healthcare coverage and reimbursement.

Pictured: Sarah Thomas, managing director, Deloitte's Center for Health Solutions, Washington D.C.

2016

The Continuing Disruption of Healthcare and Life Sciences Business Models

Cost pressures and the provisions of reform laws are driving change in the healthcare value chain. How fast and effectively is “fee for service” giving way to outcomes and capitated agreements focusing on wellness and prevention?   What will be the impact on innovative new products and intellectual property?

Pictured: Harry Greenspun, former managing director, Deloitte Center for Health Solutions

2015

Mobile Healthcare: Where Does New IT Intersect with Healthcare?

The development and widespread use of “smart phones” in the marketplace has major implications.  What is the impact of wearable technology on healthcare?  Will it be self-diagnosis or physician driven?  What about its use in clinical trials? 

Pictured: Chris Bergstrom, former chief strategy & commercial officer, WellDoc, Inc.

2014

Informatics/ “Big Data” Uses and Challenges in the Life Sciences

The use of business analytics in revealing a wide range of insights across a variety of industries. How "crunching of big data" impacts the pharmaceutical and medical device sectors. Unique to the life sciences sector, privacy requirements make it more difficult to glean information.

Pictured: Dr. Atul Butte, Priscilla Chan and Mark Zuckerberg Distinguished Professor; director, Institute for Computational Health Sciences, UCSF

2013

Public-Private Partnerships: Transferring Discoveries Out of Universities

Entrepreneurs, investors, life sciences industry business development people and university tech transfer officers share some of their “war stories” and opportunities and the pitfalls that challenge life science innovations coming to fruition.

Pictured: Dr. Anantha Shekhar, founding director, Indiana Clinical and Translational Sciences Institute

2012

Lessons From the Life Sciences "School of Hard Knocks"

From start-ups and established life sciences companies share a variety of the mistakes they have made “along the way” and the lessons learned from them. In certain areas like California and certain companies, such mistakes are celebrated as building blocks on the way to success.

Pictured: Ron Dollens, former CEO, Guidant Corporation

2011

Powering Life Sciences Entrepreneurship in Indiana

The state of entrepreneurship in Indiana’s life sciences economy and insights into the opportunities that exist for their organizations to play a role.

2010

Personalized Medicine—Are We There Yet?

More effective and efficient personalized or tailored medicine is now before us. Much like advances seen over the years with the adoption of the computer and its many applications, and the Internet, the life sciences industry will see dramatic and creative utilization of the human genome map, health informatics and technology, and a much more effective utilization of diagnostic devices and biomarkers with pharmaceuticals.

Pictured: John Lechleiter, former president, CEO, and chairman of the board, Eli Lilly & Company

2009

Strategic Collaborations in the Life Sciences

Collaboration between and among individuals, universities, and businesses and the sharing of information, ideas and effort translates to idea (product and service) development, raising of resources and capital, commercialization activities and to create a stimulating and robust life sciences industry.

Pictured: The late Bill Cook, founder and CEO of Cook Incorporated

2008

Untangling Global Life Sciences Intellectual Property Issues

Protecting the considerable investment in intellectual property that is required in the globally competitive life sciences industries is a critical component of success. This conference will explore many practical issues related to both U.S. and international intellectual property specific to the life sciences.

2007

Biological and Physiological Differences Across the Population: Implications for Research & Development Along the Life Sciences Value Chain

Biological and physiological differences among all of us are important factors impacting disease incidence. Life sciences organizations from our research universities to our pharmaceutical, medical device and biotech companies, must take these variations into account in research and development in order to optimize diagnostic and therapeutic solutions.

2006

Combination Products in the Life Sciences Industries

Indiana is rich in assets throughout the life sciences industries from our research and academic institutions to our drug, device, and biologic companies throughout the state. With Indiana's assets in various sectors, it is an appropriate place to explore the possibilities of collaboration and partnership to bring technologies together for the good of patient care around the world.

Pictured: Linda Malkas, former Vera Bradley Chair of Oncology, IU School of Medicine